Download PDF
Thromb Haemost 1988; 59(03): 426-431
DOI: 10.1055/s-0038-1647509
Original Article
Schattauer GmbH Stuttgart

A Fibrin Specific Monoclonal Antibody which Interferes with the Fibrinolytic Effect of Tissue Plasminogen Activator

P E Gargan
American Biogenetic Sciences and the Lobund Laboratory, University of Notre Dame, Notre Dame, Indiana, USA
,
V A Ploplis
American Biogenetic Sciences and the Lobund Laboratory, University of Notre Dame, Notre Dame, Indiana, USA
,
J D Scheu
American Biogenetic Sciences and the Lobund Laboratory, University of Notre Dame, Notre Dame, Indiana, USA
› Author Affiliations
Further Information

Publication History

Received 22 January 1987

Accepted after revision 04 February 1988

Publication Date:
29 June 2018 (online)

Also available at
  PDF Download Permissions and Reprints

Summary

Monoclonal antibodies to human fibrin have been prepared from stable hybridomas, obtained by fusion of a mouse myeloma cell line (NS-1) and spleen cells of Balb/c mice immunized with a suspension of human fibrin. One cell line, DG1, producing a monoclonal antibody of the IgG1 κ subclass, reacted specifically with human fibrin (KD = 1.2 nM). Western blotting analysis indicates that DG1 crossreacts with the fibrin fragment D-dimer. Using both a chromogenic and an 125I-fibrin release assay it was illustrated that in the presence of the fibrin specific antibody the t-PA mediated generation of plasmin was significantly inhibited.

An animal model system, developed to monitor thrombosis and induced reactive fibrinolysis, was used to investigate the interference of plasminogen activation, by the antibody, in vivo.

This fibrin specific antibody prolonged the onset of reactive fibrinolysis in a dose dependent manner.

Keywords

Fibrin specific antibody - Tissue plasminogen activator
 

  • References

  • 1 Blomback T, Hessel B, Hogg D, Therildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature 1978; 275: 501-504
    CrossrefPubMedGoogle Scholar
  • 2 Kanaide H, Shainoff JR. Cross-linking of fibrinogen and fibrin by fibrin stabilising factor (factor XIIIa). J Lab Clin Med 1975; 86: 100-111
    PubMedGoogle Scholar
  • 3 Doolittle RF. Fibrinogen and fibrin. Annu Rev Biochem 1984; 53: 195-229
    CrossrefPubMedGoogle Scholar
  • 4 Joist JH. Fibrinopeptide A in the diagnosis and treatment of deep venous thrombosis and pulmonary embolism. Clin Lab Med 1984; 4 (02) 363-381
    CrossrefPubMedGoogle Scholar
  • 5 Gaffney PJ. Fibrin fragmentation by plasmin: Molecular considerations and their relevance. In: Fibrinogen, Recent Biochemical andMedical Aspects. Henschen A, Graeff H, Lottspeich F. (eds) Walter de Gruyter; Berlin: 1982: 307-327
    Google Scholar
  • 6 Bick RL. The clinical significance of fibrinogen degradation products. Semin Thromb Haemostas 1982; 8: 302-330
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Allington MJ. Detection of fibrin(ogen) degradation products by a latex clumping method. Scand J Haematol 1971; 13: 115
    PubMedGoogle Scholar
  • 8 Merskey C, Kleine GI, Johnson AJ. Quantitative estimation of split products of fibrinogen in human serum relative to diagnosis and treatment. Blood 1966; 28: 1-18
    PubMedGoogle Scholar
  • 9 Gordon YB, Martin MJ, Landon J, Chard T. Development of radioimmunoassays for fibrinogen degradation products: fragments D and E. Br J Haematol 1974; 29: 109-119
    PubMedGoogle Scholar
  • 10 Nossel HL, Butler VP, Wilner GD, Canfield RE, Harfenist EJ. Specificity of antisera to human fibrinopeptide A used in clinical fibrinopeptide A assays. Thromb Haemostas 1976; 35: 101-109
    PubMedGoogle Scholar
  • 11 Plow EF, Edgington TS. Discriminating neoantigenic differences between fibrinogen and fibrin derivatives. Proc Natl Acad Sci USA 1973; 70: 1169-1173
    CrossrefPubMedGoogle Scholar
  • 12 Budzynski AZ, Marder VJ, Parker ME, Shames P, Brizuela BS, Olexa SA. Antigenic markers on fragment DD: A unique plasmic derivative of human crosslinked fibrin. Blood 1979; 54: 794-804
    PubMedGoogle Scholar
  • 13 Bosnajakovic VB, Jankovic BD, Horvat J, Cvoric J. Radiolabelled anti-human fibrin antibody: A new thrombus detecting agent. Lancet 1979; 8009: 452-454
    PubMedGoogle Scholar
  • 14 Plow EF, Edgington TS. Surface markers of fibrinogen and its physiologic derivatives revealed by antibody probes. Semin Thromb Haemostas 1982; 8 (01) 36-56
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Koehler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497
    CrossrefPubMedGoogle Scholar
  • 16 Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983; 22: 1129-1132
    PubMedGoogle Scholar
  • 17 Scheefers-Borchel U, Müller-Berghaus G, Fughe P, Eberle R, Heimburger N. Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide. Proc Natl Acad Sci USA 1985; 82: 7091-7095
    CrossrefPubMedGoogle Scholar
  • 18 Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, Whitaker AN. Measurement of crosslinked fibrin degradation products. An immunoassay using monoclonal antibodies Thromb Haemostas 1983; 50: 591-594
    PubMedGoogle Scholar
  • 19 Kudryk B, Rohoza. Ahadi M, Chin J, Wiebe ME. Specificity of a monoclonal antibody for the NH2-terminal region of fibrin. Mol Immunol 1984; 21: 89-94
    CrossrefPubMedGoogle Scholar
  • 20 Deutsch DG, Mertz ET. Plasminogen: Purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
    CrossrefPubMedGoogle Scholar
  • 21 Brockway WJ, Castellino FJ. Measurement of the binding of antifibrinolytic amino acids to various plasminogens. Arch Biochem Biophys 1972; 151: 194-199
    CrossrefPubMedGoogle Scholar
  • 22 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
    PubMedGoogle Scholar
  • 23 Varadi A, Patthy L. Location of plasminogen binding sites in human fibrin(ogen). Biochemistry 1983; 22: 2440-2446
    CrossrefPubMedGoogle Scholar
  • 24 Markwell MA K. A new solid-state reagent to iodinate proteins. Anal Biochem 1982; 125: 427-432
    CrossrefPubMedGoogle Scholar
  • 25 Drapier JC, Tenu JO, Lemaire G, Petit JF. Regulation of plasminogen activator secretion in mouse peritoneal macrophages. Biochemie 1979; 61: 463-471
    CrossrefPubMedGoogle Scholar
  • 26 Unkeless JC, Tobia A, Ossowski L, Quigly JP, Rifkin DB, Reich E. An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. J Exp Med 1973; 137: 85-111
    CrossrefPubMedGoogle Scholar
  • 27 Oi VT, Herzenberg LA. Immunoglobulin producing hybrid cell lines. In: Selected Methods in Cellular Immunology. Mishell BB, Shiigi SM. (eds) San Francisco, CA: 1980: 351-372
    Google Scholar
  • 28 Gemski MJ, Doctor BP, Gentry MK, Pluskal MG, Strickler MP. Single step purification of monoclonal antibody from murine ascites and tissue culture fluids by anion exchange high performance liquid chromatography. Biotechniques 1985; 3 (05) 378-384
    PubMedGoogle Scholar
  • 29 Law H, Lingwood CA. Use of fluorescent standards in protein transfer and immunoblotting. Accurate estimation of the molecular weight of immunoreaetive species Anal Biochem 1985; 149: 404-408
    CrossrefPubMedGoogle Scholar
  • 30 Frankel ME, Gerhard W. The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay. An analysis of the interaction between hybridoma proteins and influenza virus Mol Immunol 1979; 16: 101-106
    CrossrefPubMedGoogle Scholar
  • 31 Ploplis VA, Cummings HS, Castellino FJ. Monoclonal antibodies to discrete regions of human Glu-Plasminogen. Biochemistry 1982; 21: 5891-5897
    CrossrefPubMedGoogle Scholar
  • 32 Soria J, Soria C, Mirshahi M, Boucheix C, Aurengo A, Perrot J, Bemadou A, Samama M, Rosenfeld C. Conformational change in fibrinogen induced by adsorption to a surface. J Colloid Interface Sci 1985; 107 (01) 204-208
    CrossrefPubMedGoogle Scholar